Fast Track Treatment Continues to Make Progress
February 7, 2012 -- On June 6, 2011, the Prostate Cancer Foundation reported promising Phase III clinical trial results for Radium-223 (Alpharadin) that were presented at the annual American Society of Clinical Oncology meeting in Chicago. The data showed the compound significantly improved overall survival in patients with castration-resistant prostate cancer that has metastasized to the bone. And, in late 2011, the treatment received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in patients with bone metastases.
The article below highlights the continued progress and success of Radium-223, presented at the Genitourinary Cancers Symposium in February 2012, by Drs. A. Oliver Sartor, Laborde Professor of Cancer Research at Tulane University, New Orleans, and medical director of the Tulane Cancer Center, and Dr. Chris Parker of the Royal Marsden NHS Foundation Trust in Sutton, England.